Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
Ainos (NASDAQ:AIMD) has announced its AI Nose technology for robotics applications and launched the Ainos Alliance initiative, inviting global robotics companies to collaborate. The AI Nose technology, developed over nearly a decade, combines AI and MEMS gas sensors to enable robots to detect smells, targeting applications in home safety, healthcare, and industrial environments.
The technology offers capabilities including gas leak detection, disease detection through VOC analysis, and environmental monitoring. This announcement comes amid significant market growth projections, with the global robotics market expected to reach $178.63 billion by 2030, and the electronic nose market projected to hit $65.79 billion by 2031.
Through the Ainos Alliance, robotics companies can access this patented technology to enhance their products' capabilities in industrial safety, healthcare, and smart living applications.
Ainos (NASDAQ:AIMD) ha annunciato la sua tecnologia AI Nose per applicazioni robotiche e lanciato l'iniziativa Ainos Alliance, invitando le aziende robotiche globali a collaborare. La tecnologia AI Nose, sviluppata nel corso di quasi un decennio, combina sensori di gas MEMS e intelligenza artificiale per permettere ai robot di rilevare odori, mirando ad applicazioni nella sicurezza domestica, nella sanità e negli ambienti industriali.
Questa tecnologia offre funzionalità come la rilevazione di perdite di gas, la diagnosi di malattie attraverso l'analisi di VOC e il monitoraggio ambientale. Questo annuncio arriva in un contesto di significative previsioni di crescita del mercato, con il mercato globale della robotica atteso a raggiungere i 178,63 miliardi di dollari entro il 2030 e il mercato del naso elettronico previsto in crescita fino a 65,79 miliardi di dollari entro il 2031.
Attraverso l'Ainos Alliance, le aziende robotiche possono accedere a questa tecnologia brevettata per migliorare le capacità dei loro prodotti in materia di sicurezza industriale, sanità e applicazioni di vita intelligente.
Ainos (NASDAQ:AIMD) ha anunciado su tecnología AI Nose para aplicaciones robóticas y ha lanzado la iniciativa Ainos Alliance, invitando a empresas robóticas de todo el mundo a colaborar. La tecnología AI Nose, desarrollada durante casi una década, combina sensores de gas MEMS con inteligencia artificial para permitir que los robots detecten olores, enfocándose en aplicaciones de seguridad en el hogar, atención médica y entornos industriales.
Esta tecnología ofrece capacidades como la detección de fugas de gas, la detección de enfermedades a través del análisis de compuestos orgánicos volátiles (COV) y el monitoreo ambiental. Este anuncio se produce en medio de proyecciones de crecimiento significativas para el mercado, con el mercado global de robótica que se espera que alcance los 178.63 mil millones de dólares para 2030, y el mercado de narices electrónicas proyectado para alcanzar los 65.79 mil millones de dólares para 2031.
A través de la Ainos Alliance, las empresas robóticas pueden acceder a esta tecnología patentada para mejorar las capacidades de sus productos en áreas de seguridad industrial, atención médica y aplicaciones para una vida inteligente.
Ainos (NASDAQ:AIMD)는 로봇 응용 프로그램을 위한 AI Nose 기술을 발표하고, 글로벌 로봇 기업들이 협력할 수 있도록 초대하는 Ainos Alliance 이니셔티브를 시작했습니다. 거의 10년에 걸쳐 개발된 AI Nose 기술은 AI와 MEMS 가스 센서를 결합하여 로봇이 냄새를 감지할 수 있게 하며, 가정 안전, 의료 및 산업 환경에서의 적용을 목표로 하고 있습니다.
이 기술은 가스 누출 감지, 휘발성 유기 화합물(VOC) 분석을 통한 질병 감지 및 환경 모니터링과 같은 기능을 제공합니다. 이러한 발표는 상당한 시장 성장 전망 가운데 이루어졌으며, 글로벌 로봇 시장은 2030년까지 1786억 3천만 달러에 이를 것으로 예상되고, 전자 코 시장은 2031년까지 657억 9천만 달러에 도달할 것으로 예상됩니다.
Ainos Alliance를 통해 로봇 기업들은 이 특허 기술에 접근하여 산업 안전, 의료 및 스마트 생활 응용 프로그램에서 제품의 능력을 향상시킬 수 있습니다.
Ainos (NASDAQ:AIMD) a annoncé sa technologie AI Nose pour des applications robotiques et a lancé l'initiative Ainos Alliance, invitant les entreprises robotiques du monde entier à collaborer. La technologie AI Nose, développée pendant près d'une décennie, combine des capteurs de gaz MEMS et de l'intelligence artificielle pour permettre aux robots de détecter les odeurs, visant des applications dans la sécurité domestique, les soins de santé et les environnements industriels.
Cette technologie offre des capacités telles que la détection de fuites de gaz, la détection de maladies par l'analyse des COV et la surveillance environnementale. Cet annonce survient au milieu de prévisions de croissance significatives pour le marché, le marché mondial de la robotique étant attendu à atteindre 178,63 milliards de dollars d'ici 2030, et le marché du nez électronique devrait atteindre 65,79 milliards de dollars d'ici 2031.
Grâce à l'Ainos Alliance, les entreprises robotiques peuvent accéder à cette technologie brevetée pour améliorer les capacités de leurs produits dans les domaines de la sécurité industrielle, des soins de santé et des applications de vie intelligente.
Ainos (NASDAQ:AIMD) hat seine AI Nose-Technologie für robotische Anwendungen vorgestellt und die Ainos Alliance-Initiative gestartet, die globale Robotikunternehmen zur Zusammenarbeit einlädt. Die über fast ein Jahrzehnt entwickelte AI Nose-Technologie kombiniert KI mit MEMS-Gassensoren, um Robotern das Riechen von Gerüchen zu ermöglichen, mit dem Ziel, Anwendungen in den Bereichen Haussicherheit, Gesundheitsversorgung und Industrieumgebungen zu entwickeln.
Die Technologie bietet Funktionen wie die Erkennung von Gaslecks, die Diagnose von Krankheiten durch VOC-Analysen und die Überwachung der Umwelt. Diese Ankündigung erfolgt inmitten signifikanter Marktwachstumsprognosen, wobei der globale Robotikmarkt bis 2030 auf 178,63 Milliarden US-Dollar geschätzt wird und der Markt für elektronische Nasen bis 2031 voraussichtlich 65,79 Milliarden US-Dollar erreichen wird.
Durch die Ainos Alliance können Robotikunternehmen auf diese patentierte Technologie zugreifen, um die Fähigkeiten ihrer Produkte im Bereich industrielle Sicherheit, Gesundheitsversorgung und intelligente Wohnanwendungen zu verbessern.
- Patent-protected AI Nose technology ready for commercial applications
- Targeting multiple high-growth markets (robotics, healthcare, industrial safety)
- Operating in electronic nose market projected to reach $65.79B by 2031
- None.
Insights
The AI Nose technology announcement, while innovative, represents more of a marketing initiative than a concrete business development. Despite the impressive market projections cited (
Technology Readiness Assessment: The announcement lacks specific technical specifications, deployment timelines, or existing partnerships. The invitation for collaboration suggests the technology may still be in early development stages, with significant work needed before commercialization.
Market Position Analysis: While the electronic nose market shows promising growth (
Commercial Viability: The broad range of applications mentioned (home safety, healthcare, industrial) suggests a lack of focused market strategy, which could dilute development efforts and extend time-to-market.
The market opportunity appears substantial, but several red flags emerge in this announcement:
- No mention of existing partnerships or pilot programs
- Absence of revenue projections or monetization strategy
- Lack of competitive differentiation details
The company's tiny market cap (
Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell
SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday environments.
Ainos is now inviting robotics and humanoid companies worldwide to join its Ainos Alliance, leveraging nearly a decade of research, development, and success in this field. With multiple patents secured, AI Nose represents the culmination of years of innovation and is poised to lead the next wave of advancements in robotics. This is the perfect time to collaborate and integrate this groundbreaking technology into next-generation robots.
AI Nose is a Game-Changer, Elevating Robot's Interaction with Our World
1. Transforming Home Safety
Detects gas leaks, burning odors, and other safety hazards, sending immediate alerts to prevent accidents.
Enhances smart home environments by proactively addressing unpleasant odors, such as those from kitchen waste.
2. Revolutionizing Healthcare
Enables non-invasive early detection of diseases by analyzing volatile organic compounds (VOCs) emitted by you.
Provides real-time health monitoring for chronic disease patients, offering smarter healthcare solutions.
3. Enhancing Industrial and Environmental Safety
Detects hazardous gas leaks with precision, improving workplace safety and driving smart manufacturing.
Supports environmental protection efforts by monitoring air pollutants in real-time, providing actionable data for policy-making.
The Perfect Time to Act: A Thriving Robotics Market
1. Explosive Growth in Robotics
The global robotics market is projected to grow from
(Source: Mordor Intelligence)
2. Increasing Demand for Industrial Robots
In 2023, 541,302 industrial robots were installed globally, the second highest installation in history, with
(Source: International Federation of Robotics)
3. Humanoid Robots on the Rise
The humanoid robot market is expected to expand from
(Source: Coherent Market Insights)
4. The Growing Need for Smell Technology
The electronic nose market is projected to grow from
(Source: Coherent Market Insights)
Join the Ainos Alliance Now
Ainos' AI Nose technology harnesses nearly 10 years of dedicated research and development. Securing multiple patents along the way, the company has established itself as a pioneer in olfactory sensing technology. By joining the Ainos Alliance, robotics and humanoid companies can gain access to this disruptive and patented technology, ensuring a competitive edge in a rapidly growing market.
Key Benefits of Joining the Ainos Alliance:
Leverage Decades of Expertise: Collaborate with a proven leader in AI and sensory technology.
Secure First-Mover Advantage: Integrate AI Nose Technology into your products to capture market share.
Expand Applications: Unlock new possibilities in industrial safety, healthcare, and smart living.
Shape the Future Together: Collaborate on groundbreaking innovations that redefine the capabilities of robots.
"Originated from healthcare use-case, our AI Nose technology represents nearly a decade of innovation and perseverance," said Chun-Hsien (Eddy) Tsai, CEO of Ainos. "With the robotics and humanoid markets experiencing unprecedented growth, this is the moment to act. Partnering with us now means joining a team with a proven track record of success and ensuring your company's position at the forefront of the industry."
To join the Ainos Alliance or learn more about AI Nose, contact us today:
Media and Partnership: info@ainos.com
Investor relation: ir@ainos.com
Website: www.ainos.com
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify our commitment to enabling AI with the ability to smell and individuals to live healthier. Our clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. Follow Ainos on X, formerly known as Twitter, (@AinosInc), LinkedIn, and Webull Corporate Connect to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
FAQ
What is Ainos (AIMD) AI Nose technology and how does it work?
What market size is Ainos (AIMD) targeting with its AI Nose technology?
What are the main applications of Ainos (AIMD) AI Nose technology?
What is the Ainos Alliance and how can companies participate?
